110 related articles for article (PubMed ID: 23763922)
1. Aggressive behavior and elevated lactate dehydrogenase at baseline confer inferior prognosis in patients with primary cutaneous lymphoma.
Liu WP; Song YQ; Zheng W; Wang XP; Ding N; Zhu J
Clin Lymphoma Myeloma Leuk; 2013 Oct; 13(5):534-40. PubMed ID: 23763922
[TBL] [Abstract][Full Text] [Related]
2. Primary cutaneous non-Hodgkin's lymphoma with aggressive histology: inferior outcome is associated with peripheral T-cell type and elevated lactate dehydrogenase, but not extent of cutaneous involvement.
Visco C; Medeiros LJ; Jones D; Smith T; Rodriguez MA; McLaughlin P; Romaguera J; Cabanillas F; Sarris AH
Ann Oncol; 2002 Aug; 13(8):1290-9. PubMed ID: 12181254
[TBL] [Abstract][Full Text] [Related]
3. Prognostic value of blood eosinophilia in primary cutaneous T-cell lymphomas.
Tancrède-Bohin E; Ionescu MA; de La Salmonière P; Dupuy A; Rivet J; Rybojad M; Dubertret L; Bachelez H; Lebbé C; Morel P
Arch Dermatol; 2004 Sep; 140(9):1057-61. PubMed ID: 15381544
[TBL] [Abstract][Full Text] [Related]
4. Prognostic value of C-reactive protein, lactase dehydrogenase and anemia in recurrent or refractory aggressive lymphoma.
Suzuki K; Terui Y; Nishimura N; Mishima Y; Sakajiri S; Yokoyama M; Takahashi S; Tsuyama N; Takeuchi K; Hatake K
Jpn J Clin Oncol; 2013 Jan; 43(1):37-44. PubMed ID: 23166385
[TBL] [Abstract][Full Text] [Related]
5. Primary localized stages I and II non-Hodgkin's lymphoma of the nasopharynx: a retrospective 17-year single institutional experience.
Mohammadianpanah M; Ahmadloo N; Mozaffari MA; Mosleh-Shirazi MA; Omidvari S; Mosalaei A
Ann Hematol; 2009 May; 88(5):441-7. PubMed ID: 18931844
[TBL] [Abstract][Full Text] [Related]
6. A retrospective analysis of 144 patients with aggressive non-Hodgkin's lymphoma: impact of autologous stem cell transplantation in first remission on outcome.
Fanin R; Sperotto A; Ruiz De Elvira C; Zaja F; Stocchi R; Geromin A; Cerno M; Patriarca F; Fanni Canelles M; Damiani D; Baccarani M
Haematologica; 2000 Sep; 85(9):943-51. PubMed ID: 10980633
[TBL] [Abstract][Full Text] [Related]
7. [Clinical features and treatment outcomes of peripheral T-cell lymphoma, unspecified: a report of 78 cases].
Yu YX; Shi YK; He XH; Zhou LQ; Zhou SY; Dong M; Feng FY; Sun Y
Zhonghua Yi Xue Za Zhi; 2007 Oct; 87(38):2714-6. PubMed ID: 18167252
[TBL] [Abstract][Full Text] [Related]
8. [Prognosis and treatment strategies of primary B-cell and NK/T-cell nasopharyngeal non-Hodgkin's lymphoma at early stage].
Zou GR; Zhang YJ; Xie FY; Zheng W; Li HX; Xia YF; Lin TY; Lu TX
Ai Zheng; 2006 Dec; 25(12):1543-9. PubMed ID: 17166383
[TBL] [Abstract][Full Text] [Related]
9. Lomustine (chloroethylnitrosourea [CCNU]), ifosfamide, bleomycin, vincristine, and cisplatin (CIBO-P) is an effective regimen for patients with poor prognostic refractory or multiple disease recurrent aggressive non-Hodgkin lymphoma.
Musolino A; Perrone MA; Michiara M; Delnevo D; Franciosi V; Di Blasio B; Ceci G; Camisa R; Ardizzoni A; Cocconi G
Cancer; 2005 May; 103(10):2109-17. PubMed ID: 15803492
[TBL] [Abstract][Full Text] [Related]
10. Prognostic factors in metastatic melanoma patients treated with biochemotherapy and maintenance immunotherapy.
Minor DR; Moore D; Kim C; Kashani-Sabet M; Venna SS; Wang W; Boasberg P; O'Day S
Oncologist; 2009 Oct; 14(10):995-1002. PubMed ID: 19776094
[TBL] [Abstract][Full Text] [Related]
11. Long-term follow-up of short intensive multiagent chemotherapy without high-dose methotrexate ('Orange') in children with advanced non-lymphoblastic non-Hodgkin's lymphoma: a children's cancer group report.
Cairo MS; Krailo MD; Morse M; Hutchinson RJ; Harris RE; Kjeldsberg CR; Kadin ME; Radel E; Steinherz LJ; Morris E; Finlay JL; Meadows AT
Leukemia; 2002 Apr; 16(4):594-600. PubMed ID: 11960338
[TBL] [Abstract][Full Text] [Related]
12. Non-Hodgkin lymphoma in elderly patients: experience at Taipei Veterans General Hospital.
Bai LY; Yang MH; Chiou TJ; Liu JH; Yen CC; Wang WS; Hsiao LT; Chao TC; Chen PM
Cancer; 2003 Sep; 98(6):1188-95. PubMed ID: 12973842
[TBL] [Abstract][Full Text] [Related]
13. Primary cutaneous marginal zone B-cell lymphoma: response to treatment and disease-free survival in a series of 137 patients.
Servitje O; Muniesa C; Benavente Y; Monsálvez V; Garcia-Muret MP; Gallardo F; Domingo-Domenech E; Lucas A; Climent F; Rodriguez-Peralto JL; Ortiz-Romero PL; Sandoval J; Pujol RM; Estrach MT
J Am Acad Dermatol; 2013 Sep; 69(3):357-65. PubMed ID: 23796549
[TBL] [Abstract][Full Text] [Related]
14. [Prognosis of primary non-Hodgkin's lymphoma of the breast].
Guo HY; Zhao XM; Cao JN; Hu XC; Yin JL; Hong XN; Li J
Zhonghua Zhong Liu Za Zhi; 2008 Mar; 30(3):200-2. PubMed ID: 18756936
[TBL] [Abstract][Full Text] [Related]
15. Prognostic factors in primary gastric lymphoma.
Medina-Franco H; Germes SS; Maldonado CL
Ann Surg Oncol; 2007 Aug; 14(8):2239-45. PubMed ID: 17546474
[TBL] [Abstract][Full Text] [Related]
16. Bulky disease is an adverse prognostic factor in patients treated with chemotherapy comprised of cyclophosphamide, doxorubicin, vincristine, and prednisone with or without radiotherapy for aggressive lymphoma.
Wilder RB; Rodriguez MA; Ha CS; Pro B; Hess MA; Cabanillas F; Cox JD
Cancer; 2001 Jun; 91(12):2440-6. PubMed ID: 11413536
[TBL] [Abstract][Full Text] [Related]
17. Treatment results of chemoradiation therapy for localized aggressive lymphomas: A retrospective 20-year study.
Yamashita H; Izutsu K; Nakamura N; Shiraishi K; Chiba S; Kurokawa M; Tago M; Igaki H; Ohtomo K; Nakagawa K
Ann Hematol; 2006 Aug; 85(8):523-9. PubMed ID: 16691398
[TBL] [Abstract][Full Text] [Related]
18. [Clinical characteristics and prognosis of diffuse large B-cell lymphoma].
Yang BY; Yong WB; Zhu J; Zheng W; Zhang YT; Wang XP; Meng SN
Zhonghua Zhong Liu Za Zhi; 2005 Mar; 27(3):174-6. PubMed ID: 15946571
[TBL] [Abstract][Full Text] [Related]
19. CD56+ lymphoma with skin involvement: clinicopathologic features and classification.
Gniadecki R; Rossen K; Ralfkier E; Thomsen K; Skovgaard GL; Jønsson V
Arch Dermatol; 2004 Apr; 140(4):427-36. PubMed ID: 15096371
[TBL] [Abstract][Full Text] [Related]
20. Survival outcomes and prognostic factors in mycosis fungoides/Sézary syndrome: validation of the revised International Society for Cutaneous Lymphomas/European Organisation for Research and Treatment of Cancer staging proposal.
Agar NS; Wedgeworth E; Crichton S; Mitchell TJ; Cox M; Ferreira S; Robson A; Calonje E; Stefanato CM; Wain EM; Wilkins B; Fields PA; Dean A; Webb K; Scarisbrick J; Morris S; Whittaker SJ
J Clin Oncol; 2010 Nov; 28(31):4730-9. PubMed ID: 20855822
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
